A phase I trial at Ohio State reported early efficacy for next-generation CAR T cells engineered to target three B-cell proteins and co-stimulated with OX40. In relapsed B-cell blood cancers, the program manufactured CAR T cells in about six days and delivered fresh infusions with remissions observed alongside a side-effect profile described as minimal. The study directly targets two practical constraints in CAR T delivery—time to manufacture and toxicity—by combining multi-target recognition with OX40 signaling. If durability and response depth hold up in larger cohorts, it could reshape the design space for CAR T constructs aimed at heterogeneous antigen-positive malignancies. Clinically, the trial’s outcomes will likely drive further interest in rapid manufacturing and cost-of-care considerations as CAR T programs expand beyond specialized centers.